KR102723905B1 - 넥틴-4 결합 단백질 및 이의 사용 방법 - Google Patents

넥틴-4 결합 단백질 및 이의 사용 방법 Download PDF

Info

Publication number
KR102723905B1
KR102723905B1 KR1020197038453A KR20197038453A KR102723905B1 KR 102723905 B1 KR102723905 B1 KR 102723905B1 KR 1020197038453 A KR1020197038453 A KR 1020197038453A KR 20197038453 A KR20197038453 A KR 20197038453A KR 102723905 B1 KR102723905 B1 KR 102723905B1
Authority
KR
South Korea
Prior art keywords
seq
antibody
nectin
amino acid
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197038453A
Other languages
English (en)
Korean (ko)
Other versions
KR20200024788A (ko
Inventor
카렌 제인 메이릭 모리슨
페르난도 도네이트
펭 양
Original Assignee
어젠시스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어젠시스 인코포레이티드 filed Critical 어젠시스 인코포레이티드
Publication of KR20200024788A publication Critical patent/KR20200024788A/ko
Application granted granted Critical
Publication of KR102723905B1 publication Critical patent/KR102723905B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020197038453A 2017-06-05 2018-06-04 넥틴-4 결합 단백질 및 이의 사용 방법 Active KR102723905B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515454P 2017-06-05 2017-06-05
US62/515,454 2017-06-05
PCT/US2018/035840 WO2018226578A1 (en) 2017-06-05 2018-06-04 Nectin-4-binding proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
KR20200024788A KR20200024788A (ko) 2020-03-09
KR102723905B1 true KR102723905B1 (ko) 2024-10-31

Family

ID=64566092

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038453A Active KR102723905B1 (ko) 2017-06-05 2018-06-04 넥틴-4 결합 단백질 및 이의 사용 방법

Country Status (10)

Country Link
US (1) US11292837B2 (enExample)
EP (1) EP3635013A4 (enExample)
JP (1) JP7168590B2 (enExample)
KR (1) KR102723905B1 (enExample)
CN (2) CN111675761B (enExample)
BR (1) BR112019025513A2 (enExample)
CA (1) CA3065514A1 (enExample)
MX (1) MX2019014318A (enExample)
TW (1) TWI870338B (enExample)
WO (1) WO2018226578A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
CN110904073B (zh) * 2019-05-31 2020-12-01 江南大学 一种脂肪酶突变体及其在去污方面的应用
US12398206B2 (en) 2019-10-07 2025-08-26 Université D'aixmarseille Antibodies having specificity for nectin-4 and uses thereof
KR102280672B1 (ko) * 2019-12-20 2021-07-23 주식회사 베르티스 암의 진단용 조성물
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN113527486B (zh) * 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
EP4168453A4 (en) * 2020-06-18 2024-11-20 BioAtla, Inc. CONDITIONALLY ACTIVE ANTI-NECTIN-4 ANTIBODIES
MX2022016232A (es) * 2020-06-19 2023-03-14 Agensys Inc Marcadores para uso en metodos para tratar canceres con conjugados de anticuerpo y farmaco (adc).
EP4208259A2 (en) * 2020-09-04 2023-07-12 NovaRock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
CR20230128A (es) * 2020-09-16 2023-06-23 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
KR20230112656A (ko) * 2020-11-25 2023-07-27 이나뜨 파르마 에스.에이. 암의 치료
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
AU2022266934A1 (en) * 2021-04-26 2023-10-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal user thereof
EP4463483A4 (en) * 2022-01-12 2025-05-21 Navi Bio-Therapeutics, Inc. ANTIBODY SPECIFIC TO NECTIN CELL ADHESION MOLECULE 4 AND USES THEREOF
WO2023180490A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
WO2023198007A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Anti-nectin-4 antibodies and bispecific antibodies
WO2023198011A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Single domain anti-nectin-4 antibodies
WO2023198008A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Compositions and methods for treating cancer
EP4310101A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibodies and antibody-drug conjugates
WO2024059733A2 (en) * 2022-09-14 2024-03-21 Fred Hutchinson Cancer Center Chimeric antigen receptors binding nectin-4
KR102584898B1 (ko) * 2022-10-24 2023-10-04 연세대학교 산학협력단 자궁내막암 진단 방법 및 이를 이용한 키트
WO2024251260A1 (zh) * 2023-06-08 2024-12-12 江苏迈威康新药研发有限公司 结合Nectin-4的抗体及其用途
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン－４抗体及び抗体－薬物コンジュゲート
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110150886A1 (en) 2008-04-17 2011-06-23 Fusion Antibodies Limited Anti-areg/hb-egf antibodies and treatment
WO2016203053A2 (en) 2015-06-18 2016-12-22 Thomas Mole Herd Methods of characterising cancer
WO2017042210A1 (en) 2015-09-09 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111076A1 (en) * 2004-05-12 2005-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (n4) as a marker for cancer prognosis
JP2012511305A (ja) * 2008-12-12 2012-05-24 オンコセラピー・サイエンス株式会社 癌の治療および診断の標的遺伝子としてのネクチン−４
US8637642B2 (en) 2010-09-29 2014-01-28 Seattle Genetics, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110150886A1 (en) 2008-04-17 2011-06-23 Fusion Antibodies Limited Anti-areg/hb-egf antibodies and treatment
WO2016203053A2 (en) 2015-06-18 2016-12-22 Thomas Mole Herd Methods of characterising cancer
WO2017042210A1 (en) 2015-09-09 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof

Also Published As

Publication number Publication date
MX2019014318A (es) 2020-08-13
BR112019025513A2 (pt) 2020-06-23
TW201902922A (zh) 2019-01-16
CN111675761B (zh) 2023-10-20
KR20200024788A (ko) 2020-03-09
CA3065514A1 (en) 2018-12-13
RU2019144030A (ru) 2021-07-09
EP3635013A1 (en) 2020-04-15
RU2019144030A3 (enExample) 2021-12-28
US11292837B2 (en) 2022-04-05
CN111051345A (zh) 2020-04-21
WO2018226578A1 (en) 2018-12-13
US20200231670A1 (en) 2020-07-23
JP7168590B2 (ja) 2022-11-09
TWI870338B (zh) 2025-01-21
CN111675761A (zh) 2020-09-18
EP3635013A4 (en) 2021-02-24
JP2020522261A (ja) 2020-07-30
WO2018226578A8 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
KR102723905B1 (ko) 넥틴-4 결합 단백질 및 이의 사용 방법
US12378312B2 (en) Polynucleotides encoding human beta klotho antibodies or binding fragments thereof and methods of use thereof
JP2015501639A (ja) 抗ｃｄ９８抗体およびその使用方法
US20210380675A1 (en) Il-36 antibodies and uses thereof
US20250179196A1 (en) Materials and methods of making or using il-23r binding proteins
RU2805252C2 (ru) Белки, связывающие нектин-4, и способы их применения
HK40037283A (en) Nectin-4 binding proteins and methods of use thereof
HK40037283B (zh) 柄蛋白-4结合蛋白及其使用方法
HK40026608A (en) Nectin-4 binding proteins and methods of use thereof
US20250189530A1 (en) Btn1a1 binding proteins and methods of use thereof
HK40036377A (en) Antibodies binding beta klotho domain 2 and methods of use thereof
HK1229825A1 (en) Antibodies binding beta klotho domain 2 and methods of use thereof
HK1229825B (en) Antibodies binding beta klotho domain 2 and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601